157-160) Clinical and pathological features that characterize a very high-risk subgroup where a trigger for early cystectomy may be indicated include: T1HG with variant features (micropapillary, sarcomatoid, plasmacytoid
, or small cell); T1HG with LVI, multiple and/or large T1HG tumours; T1HG with concomitant bladder/prostatic CIS; persistent T1HG on restaging TUR; early high-grade recurrence at 3 months, and invasive tumours involving bladder diverticula due to the absence of a muscularis propria layer (Level of Evidence 3).
Lymphosarcoma with plasmacytoid
differentiation in a scarlet macaw (Ara macao).
Endoscopic ultrasound-guided biopsy of the pancreatic mass showed predominantly nonneoplastic pancreatic and gastrointestinal tissue with rare groups of atypical epithelioid to plasmacytoid
cells, suspicious for well-differentiated NET (Figure 2a).
Radstake~s has focused on immune cell subsets, in particular on plasmacytoid
dendritic cells (pDCs), to identify their potential role in SSc.
Features that are common to both nodular fasciitis and pleomorphic adenoma are the presence of dissociated spindle and plasmacytoid
cells with central to eccentric nuclei, clumps of intercellular stromal material, and a myxoid background.
In addition, the surrounding lymphoid tissue showed against the background of what appeared to be preceding follicular hyperplasia features of marked folliculolysis, and increased plasmacytoid
cells and plasma cells were also seen populating some of the follicles.
The aspiration was moderately cellular, containing a mixed population of spindle cells (predominantly) and epithelioid/ plasmacytoid
cells in dispersed, aggregated groups, or cohesive microtissue fragments with a fascicular arrangement (Figure 1).
The Company informed that investigators will present the following four abstracts on SL-401, a novel targeted therapy directed to the Interleukin-3 Receptor on cancer stem cells (CSCs) and Tumor Bulk, in patients with Blastic Plasmacytoid
Dendritic Cell Neoplasm (BPDCN), via poster presentation - an update on the robust clinical activity; Preclinical Studies: Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model; Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia; and Inhibits Plasmacytoid
Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance.
In parallel with our results, Xie and colleagues (22) also showed that expression levels of TLR9 mRNA and protein levels were decreased in plasmacytoid
dendritic cells of CHB patients when compared with healthy controls.
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid
dendritic cell-induced adaptive t regulatory cell generation.
This is consistent with our previous observation that plasmacytoid
dendritic cells were rapidly diminished in RPs (32).
Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid
dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy for which there is no effective treatment.